van de Locht L T, Smetsers T F, Wittebol S, Raymakers R A, Mensink E J
Central Hematology Laboratory, University Hospital Nijmegen, The Netherlands.
Leukemia. 1994 Oct;8(10):1780-4.
Patients with acute myeloid leukaemia with maturation (AML-M2) that carried the t(8;21) were tested for the presence of chimeric AML1/ETO mRNA. After RT-PCR, an expected band of 208 bp was observed on gel, as well as some slower migrating bands. The base composition of one of the additional products was determined and was found to contain a new 68-bp ETO sequence present at the fusion of AML1 and ETO genes. The derived protein sequence results in a truncated AML1 gene still containing the putative DNA binding domain. Molecular diversity in the AML1-ETO transcripts will have consequences for the detection of minimal residual disease and antisense studies.
对携带t(8;21)的急性髓细胞白血病伴成熟型（AML-M2）患者进行嵌合AML1/ETO mRNA检测。逆转录聚合酶链反应（RT-PCR）后，在凝胶上观察到一条预期的208 bp条带以及一些迁移较慢的条带。确定了其中一个额外产物的碱基组成，发现其包含一个位于AML1和ETO基因融合处的新的68 bp ETO序列。推导的蛋白质序列导致一个截短的AML1基因，该基因仍包含推定的DNA结合结构域。AML1-ETO转录本中的分子多样性将对微小残留病的检测和反义研究产生影响。
